Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
about
Cys-27 variant of human δ-opioid receptor modulates maturation and cell surface delivery of Phe-27 variant via heteromerizationPROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activityRole for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cellsExport from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptorGenetics of susceptibility to human infectious diseasePotent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140A role for chemokine receptor transactivation in growth factor signaling.Luteinizing hormone receptor ectodomain splice variant misroutes the full-length receptor into a subcompartment of the endoplasmic reticulum.A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart diseaseMultiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis.CCR5 haplotypes and mother-to-child HIV transmission in Malawi.Regulation of CCR5 expression in human placenta: insights from a study of mother-to-child transmission of HIV in Malawi.CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function.Gene expression variability within and between human populations and implications toward disease susceptibility.Emerging concepts and approaches for chemokine-receptor drug discovery.Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1Chemokine receptor oligomerization and allostery.Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transferChaperoning G protein-coupled receptors: from cell biology to therapeuticsCombined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmissionChemokine receptor homo- or heterodimerization activates distinct signaling pathways.Chemokines and their receptors in infectious disease.CCR5Δ32 genotype leads to a Th2 type directed immune response in ESRD patients.Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.Oligomerization of G-protein-coupled receptors: lessons from the yeast Saccharomyces cerevisiae.Feline immunodeficiency virus xenoinfection: the role of chemokine receptors and envelope diversity.Dopamine receptor-interacting protein 78 acts as a molecular chaperone for CCR5 chemokine receptor signaling complex organization.Consequences of ChemR23 heteromerization with the chemokine receptors CXCR4 and CCR7.Homo-oligomeric complexes of the yeast alpha-factor pheromone receptor are functional units of endocytosis.Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation.The CCR5Δ32 polymorphism in Brazilian patients with sickle cell diseaseChemokine receptors: emerging opportunities for new anti-HIV therapies.Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks.CCR5: From Natural Resistance to a New Anti-HIV Strategy.Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors
P2860
Q24300182-02303A35-379D-4F05-8A34-4B2DD8417377Q24317396-6EAFD5C2-7F71-46DF-8723-CF4537AA4783Q24608200-90ED1108-6275-40C7-9E1C-6491A85DCAAAQ28115723-594909AA-B4A6-46FB-8A93-EE3A15AF4E6AQ28208872-87B6B77C-D42C-4556-AD02-7AD0F7ABCAABQ28345395-2EED6F6E-F837-4866-829B-15EBDBD27AFCQ28360845-2077DC4C-85B0-4EE0-95DC-8B6B13D8DFE8Q28573360-DEA6D36B-D350-443C-9331-F98F6EC38D62Q28588519-1F36A24A-6AAC-41A3-BEE6-87DED64BFA08Q30857101-D4CEC342-C1E4-4047-A121-610DE40A3145Q33287486-67EFCACC-4DB2-4F07-9572-BCD0B82E4A5AQ33296998-DB9ACC49-706F-48A3-809B-DA34D3CBDF7FQ33532625-8A0C4E08-E770-49D8-9EDC-D385E57C52ADQ33654027-B36E292C-3630-49EB-9EF3-099E78B15492Q33701750-3C9F1C46-E45E-49D9-A4E3-BEDE8D6F97D7Q33763369-936EF6F5-0DE8-451B-9DA9-5F1826ADE864Q33788002-EF0D50D7-8A38-4879-A6FC-09F2ABFB5E09Q33804016-787E9EFE-9721-4AFE-9F3C-A1CB784E3E9CQ33808920-BA5ED6BB-A54C-41ED-ADF7-8C05AD5B50D2Q33810517-E7E2E60F-FB8D-4152-8F68-1547F4302D51Q33835337-C08E4FC1-248F-4498-A9B0-C87957F9A111Q33838860-246DB51B-451A-4BC5-AD1F-50C99D54301BQ33880430-43223B9F-FEFD-46A9-9F09-F4AFCEB290A7Q33927508-269096D5-B377-43A2-B864-542375A82F77Q33987424-9D62E0C5-2A86-4F95-B89F-F81459422507Q34079612-F4035CC6-54B3-4654-B8F0-CA4FC0B7F471Q34129756-5CEE741D-85D1-48AC-B4DA-22AA3A1BB8EFQ34163444-FC650A06-4274-4D96-BF89-C58F4C2A5572Q34169244-FB953DD0-F3BE-4EB1-A530-CFF83173F028Q34232914-E4E1A3A1-D968-48E1-9AE7-719675D5E47CQ34335096-5F7DB461-386D-4F8F-B4E4-FC735E3C7C6CQ34344881-60933DD7-4B6D-4DF9-9BE9-056878C8C1ACQ34612824-556E287E-95A5-461E-A862-1E5708E58405Q34748827-31F2B12B-B4D0-44BD-8EEA-C4801E60EC07Q34752104-E04FB7AE-3381-4D32-AEF2-B31700D02846Q34762728-9A1B0FC0-9B7D-4964-8153-264248ED0B35Q35050395-C11217F1-D9F6-488B-A2AC-A2A70E3E8A1EQ35131130-509CBCC9-EEBD-478A-A243-4134CC8112ACQ35260605-BB4C8EA5-906F-4789-8F7C-B57B365841CCQ35606973-70229633-7B6C-4118-BC01-F417B5F9D16A
P2860
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@ast
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@en
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@nl
type
label
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@ast
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@en
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@nl
prefLabel
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@ast
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@en
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@nl
P2093
P356
P1476
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
@en
P2093
P304
30603-30606
P356
10.1074/JBC.272.49.30603
P407
P577
1997-12-01T00:00:00Z